NIH R01 · 2025
PROJECT SUMMARY There are over half a million head and neck cancer (HNC) survivors in the United States. More than two-thirds experience chronic soft tissue swelling (lymphedema) in the head and neck region. Lymphedema not only has adverse cosmetic and psychosocial consequences but can cause a substantial impact on critical functions (e.g., swallowing) and result in decreased range of motion in the jaw, neck, and shoulders. The standard of care for acute or early-stage lymphedema is complete decongestive therapy (CDT). After completion of CDT, 30%-40% of survivors still have clinically evident residual lymphedema that can progress to chronic lymphedema. Currently, there are no proven…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.